Your CRO’s Assignment Strategy for CRAs Matters!
Monitoring the progress of clinical research is fundamental to obtaining successful outcomes because it ensures that constraints to success are…
Lessons Learned Moving Forward – Audit Readiness & Remote Close-Out Visits
The COVID-19 pandemic has required the clinical research industry to find new and innovative ways to monitor investigative sites. Although…
Lessons Learned Moving Forward – Site Support & Remote Close Out
Nearly every aspect of society, including the way scientists conduct the testing of medicines has been affected by the COVID-19…
Prime Location for Global Clinical Studies?
Canada is considered one of the most attractive places to live in the world, with a high quality of life,…
What & Where: the ‘Next Normal’ in Oncology Clinical Research
Developing oncology compounds is a constantly evolving process, and never more so than now. Pre-pandemic oncology was both the largest…
Why Not Canada for Your Phase 3 Global Trial Expansion?
Pre-pandemic oncology was both the largest and fastest growing therapeutic area in the clinical trials market. A key market trend…
Diversity in Clinical Trial Participants: Canada Holds Promise
Participant diversity in clinical trials can be quite challenging to achieve. With COVID the concern about appropriate demographic representation is…
The Canadian Landscape for Childhood Cancer Research
Pediatric Hematology Oncology is a relatively recent area of study. Only in the past 50 years have substantial advances taken…
2020 a Year Like No Other: What it Takes to Keep Ahead of Rapid Change
This time last year none of us imagined we were about to go through a year like no other, and…
Scimega, Canada’s Premier CRO, Introduces Julie Martin, CEO
Julie Martin, MSc, MBA, Lean certified, CEO and Co-owner has been part of the team at Scimega, since 2013. Her…